Bloomberg -- Merck & Co.’s experimental hepatitis C drug cures more patients than current therapies, according to U.S. regulators considering whether to clear the first treatment for the liver disease in more than a decade. Boceprevir, combined with standard treatments, worked better than those drugs alone in clinical trials, Food and Drug Administration staff said today in a preliminary review on the agency’s website. Outside advisers to the FDA will meet April 27 to evaluate the findings.
